en · de · es · pt
melanotan-2-notes.peptides7501.com › Guide › Chemistry And Receptor Pharmacology — What the Evidence Shows

Chemistry And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2026-01-13 · last reviewed 2026-02-06 · Guide

afamelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-02-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Handling, Storage and Analytical Verification

Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.

The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Related pages on this site

Handling, Storage, and Analytical Verification

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Background from the literature

=== Standardization for Japan and South Korea === Standards for UHDTV in South Korea have been developed by its Telecommunications Technology Association. On August 30, 2013, the scenarios for 4K-UHDTV service were described in the Report "TTAR 07.0011: A Study on the UHDTV Service Scenarios and its Considerations". On May 22, 2014, the technical report "TTAR-07.0013: Terrestrial 4K UHDTV Broadcasting Service" was published. On October 13, 2014, an interim standard – "TTAI.KO-07.0123: Transmission and Reception for Terrestrial UHDTV Broadcasting Service" – was published based on HEVC encoding, with MPEG 2 TS, and DVB-T2 serving as the standards. On June 24, 2016, a standard – "TTAK.KO-07.0127: Transmission and Reception for Terrestrial UHDTV Broadcasting Service" – was published based on HEVC encoding, with MMTP/ROUTE IP, and ATSC 3.0 serving as the standards.

=== Medication === The primary medications for lung barotrauma are hyperbaric and normobaric oxygen, hyperbaric heliox or nitrox, isotonic fluids, anti-inflammatory medications, decongestants, and analgesics.

While ethical approaches to the excavation and analysis of physical human remains have received considerable attention, professional and academic dialogue regarding how to appropriately record, share, and display human remains in the digital realm is less developed. While digital technologies for recording and analysing human remains are increasingly accessible, justification for such recording and analysis is essential e.g. 3D scanning performed simply because it is possible is inappropriate and disrespectful to the deceased.

Harkin responded by elevating OAM into an independent NIH "center", just short of being its own "institute", and renamed it the National Center for Complementary and Alternative Medicine (NCCAM). NCCAM had a mandate to promote a more rigorous and scientific approach to the study of alternative medicine, research training and career development, outreach, and "integration". Stephen Strauss was the director of NCCAM from 1999 to 2006. He tried to bring more scientific rigor to the organization. In 1999 the NCCAM budget was increased from $20 million to $50 million. The United States Congress approved the appropriations without dissent. In 2000, the budget was increased to about $68 million, in 2001 to $90 million, in 2002 to $104 million, and in 2003, to $113 million.

Two species of AAV were recognised by the International Committee on Taxonomy of Viruses in 2013: adeno-associated dependoparvovirus A (formerly AAV-1, −2, −3 and −4) and adeno-associated dependoparvovirus B (formerly AAV-5). Until the 1990s, virtually all AAV biology was studied using AAV serotype 2. However, AAV is highly prevalent in humans and other primates and several serotypes have been isolated from various tissue samples. Serotypes 2, 3, 5, and 6 were discovered in human cells, AAV serotypes 1, 4, and 7–11 in nonhuman primate samples. As of 2006 there have been 11 AAV serotypes described, the 11th in 2004. AAV capsid proteins contain 12 hypervariable surface regions, with most variability occurring in the threefold proximal peaks, but the parvovirus genome in general presents highly conserved replication and structural genes across serotypes. All of the known serotypes can infect cells from multiple diverse tissue types.

Sources: en.wikipedia.org

Further detail

NpCl4 + 4 KC5H5 → Np(C5H5)4 + 4 KCl It is soluble in benzene and THF, and is less sensitive to oxygen and water than Pu(C5H5)3 and Am(C5H5)3. Other Np(IV) cyclopentadienyl compounds are known for many ligands: they have the general formula (C5H5)3NpL, where L represents a ligand. Neptunocene, Np(C8H8)2, was synthesized in 1970 by reacting neptunium(IV) chloride with K2(C8H8). It is isomorphous to uranocene and plutonocene, and they behave chemically identically: all three compounds are insensitive to water or dilute bases but are sensitive to air, reacting quickly to form oxides, and are only slightly soluble in benzene and toluene. Other known neptunium cyclooctatetraenyl derivatives include Np(RC8H7)2 (R = ethanol, butanol) and KNp(C8H8)·2THF, which is isostructural to the corresponding plutonium compound. In addition, neptunium hydrocarbyls have been prepared, and solvated triiodide complexes of neptunium are a precursor to many organoneptunium and inorganic neptunium compounds.

=== PPAR-delta agonists === PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids. In August 2024, seladelpar became the first PPARδ agonist to be approved for clinical use.

This could provide a pathway from fatty acids to glucose, but whether this actually happens in the human body is controversial. Although most gluconeogenesis occurs in the liver, the relative contribution of gluconeogenesis by the kidney is increased in diabetes and prolonged fasting. The gluconeogenesis pathway is highly endergonic until it is coupled to the hydrolysis of ATP or GTP, effectively making the process exergonic. For example, the pathway leading from pyruvate to glucose-6-phosphate requires 4 molecules of ATP and 2 molecules of GTP to proceed spontaneously. These ATPs are supplied from fatty acid catabolism via beta oxidation.

=== Chromatography === Liquid chromatography is an important tool in the study of the proteome. It allows for very sensitive separation of different kinds of proteins based on their affinity for a matrix. Some newer methods for the separation and identification of proteins include the use of monolithic capillary columns, high temperature chromatography and capillary electrochromatography.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

Why is the lyophilized form preferred?

The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.

Network